Head-to-head evidence
tamoxifen vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
tamoxifen
Marketed by Mayne Pharma
NCT00066690 · Phase 3 · completed
The trial was large and randomized, with tamoxifen as an active comparator, but it was open-label rather than blinded. Its hard primary endpoint, five-year disease-free survival, produced mixed results: exemestane plus ovarian suppression was superior to tamoxifen alone, whereas tamoxifen plus ovarian suppression was not statistically significant compared with tamoxifen alone.
Next expected readout: October 2026 · NCT03707340 (registry estimate)
Vepdegestrant
Marketed by Rigel Pharmaceuticals and partners
NCT04072952 · Phase 1/2 · completed
The study enrolled 219 participants but was non-randomized, open-label, and lacked a control group; its primary outcomes focused mainly on dose-limiting toxicities, adverse events, and laboratory abnormalities rather than a controlled efficacy comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT05573555 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tamoxifen's landscape · Vepdegestrant's landscape